AMCoR Asahikawa Medical College
HOME
|

AMCoR:Asahikawa Medical University Collection and Research (旭川医科大学学術成果リポジトリ)は、本学で生産された電子的な知的生産物(学術雑誌論文の原稿・教材・学術資料など)を保存し、原則的に無償で発信するためのインターネット上の保管庫です。

※AMCoRに収録された学術論文のほとんどは、商業出版社や学会出版社の学術雑誌に掲載されたものですが、著作権に係わる出版社の方針により、出版社の条件に添った版を収録しています。そのため実際の誌面とはレイアウトの相違や、字句校正による文言の違いがあり得ますことをあらかじめご了承ください。


| ホーム ニュース ログイン |

Language

AMCoR検索
  
     詳細検索

インデックスツリー

詳細



閲覧数:375
ID 20220930_K583
アイテムタイプ Article
このアイテムを表示する
本文 K583 Yajima Yuki_TD.pdf
Type : application/pdf Download
Size : 1.1 MB
Last updated : Oct 7, 2022
Downloads : 533

Total downloads since Oct 7, 2022 : 533
タイトル A tumor metastasis-associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity (TWIST1特異的ヘルパーT細胞の活性化を応用したがん免疫療法に関する研究)
著者
矢島, 優己 (Yajima, Yuki)
上位タイトル
Cancer science Vol.113, No.8  (2022. 8) ,p.2526- 2535
識別番号
ISSN
1347-9032
DOI 10.1111/cas.15429
その他
PMID:35579200
博士論文情報
学位授与番号 10107A583
学位授与年月日 2022-09-30
学位名 博士(医学)
学位授与機関 旭川医科大学
抄録 Although neoantigens are one of the most favorable targets in cancer immunotherapy, it is less versatile and costly to apply neoantigen-derived cancer vaccines to patients due to individual variation. It is, therefore, important to find highly immunogenic antigens between tumor-specific or associated antigens that are shared among patients. Considering the cancer immunoediting theory, immunogenic tumor cells cannot survive in the early phase of tumor progression including two processes: elimination and equilibrium. We hypothesized that highly immunogenic molecules are allowed to be expressed in tumor cells after an immune suppressive tumor microenvironment was established, if these molecules contribute to tumor survival. In the current study, we focused on TWIST1 as a candidate for highly immunogenic antigens because it is upregulated in tumor cells under hypoxia and promotes tumor metastasis, which is observed in the late phase of tumor progression. We demonstrated that TWIST1 had an immunogenic peptide sequence TWIST1140-162 , which effectively activated TWIST1-specific CD4+ T-cells. In a short-term culture system, we detected more TWIST1-specific responses in breast cancer patients compared with in healthy donors. Vaccination with the TWIST1 peptide also showed efficient expansion of TWIST1-reactive HTLs in humanized mice. These findings indicate that TWIST1 is a highly immunogenic shared antigen and a favorable target for cancer immunotherapy.
キーワード
cancer immunoediting
cancer immunotherapy
cancer vaccine
metastasis-associated molecules
shared
tumor antigens
vaccination therapy
言語
eng
資源タイプ application/pdf
ジャンル Thesis or Dissertation
著者版フラグ ETD
Index
/ Public
/ Public / 学位論文
/ Public / 学位論文 / 博士論文2020.3~
関連アイテム